...raised by the antibody company since its founding in 2015 to $60 million. Existing investors Heritas...

...board as an independent director. Temasek led the financing. EDBI, Karst Peak Capital, Heliconia and Heritas...

...board as an independent director. Temasek led the financing. EDBI, Karst Peak Capital, Heliconia and Heritas...
...TT10 to treat nasopharyngeal cancer. The therapy comprises Epstein-Barr virus (EBV)-specific autologous cytotoxic T lymphocytes. Allison Johnson TT10 EDBI Heliconia Heritas Karst...

...million in an undisclosed financing round led by Temasek. EDBI, Karst Peak Capital, Heliconia and Heritas...